CymaBay Therapeutics Inc (DELISTED) (CBAY:DL)
32.48
0.00 (0.00%)
USD |
NASDAQ |
Mar 25, 16:00
CymaBay Therapeutics Research and Development Expense (Annual): 80.80M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 80.80M |
| December 31, 2022 | 68.00M |
| December 31, 2021 | 64.54M |
| December 31, 2020 | 35.88M |
| December 31, 2019 | 83.84M |
| December 31, 2018 | 58.12M |
| Date | Value |
|---|---|
| December 31, 2017 | 18.94M |
| December 31, 2016 | 15.94M |
| December 31, 2015 | 17.03M |
| December 31, 2014 | 15.82M |
| December 31, 2013 | 4.525M |
| December 31, 2012 | 9.28M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
35.88M
Minimum
2020
83.84M
Maximum
2019
66.61M
Average
68.00M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Gilead Sciences Inc | 5.718B |
| Assure Holdings Corp | -- |
| Societal CDMO Inc (DELISTED) | -- |
| AN2 Therapeutics Inc | 54.87M |
| Madrigal Pharmaceuticals Inc | 272.35M |